Company Overview: CLVS

Upcoming Projects (CLVS)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (CLVS)

Examining the recent TRITON3 Phase 3 Clinical Data of Rubraca (rucaparib) from Clovis Oncology for the Treatment of Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations.
Ticker: CLVS
Executed On: Oct 26, 2022 at 09:30 AM EDT

Expired Projects (CLVS)

A Second View: Examining the recent TRITON3 Phase 3 Clinical Data of Rubraca (rucaparib) from Clovis Oncology for the Treatment of Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations.
Ticker: CLVS
Execute By: Nov 18, 2022
Cancer-associated fibroblasts (CAFs) as a promising therapeutic target
Ticker: CLVS
Execute By: Sep 04, 2020
Discussing the Market Potential and Chances of Approval for Clovis' (CLVS) Rociletinib in Mutant Epidermal Growth Factor Receptor (EGFR) Non-Small Cell Lung Cancer (NSCLC) Ahead of April 12 FDA Oncologic Drugs Advisory Committee Review
Ticker: CLVS
Execute By: Apr 01, 2016

Upcoming & Overdue Catalysts (CLVS)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (CLVS)

Clovis Oncology (CLVS) Presented Rubraca (Rucaparib) And Lucitanib Data At 2021 ASCO Annual Meeting
Ticker: CLVS
Occurred on: Jun 08, 2021
Journal Of Clinical Oncology Publishes Additional Data From Clovis Oncology’s (CLVS) TRITON2 Clinical Trial Evaluating Rubraca (Rucaparib) For The Treatment Of MCRPC In Patients With BRCA1/2 Gene Mutations
Ticker: CLVS
Occurred on: Aug 17, 2020
Clovis Oncology (CLVS) discloses termination of Phase 2 ATLAS study of Rubraca (rucaparib) alone in relapsed/metastatic bladder cancer due to lack of efficacy
Ticker: CLVS
Occurred on: Apr 12, 2019
Clovis (CLVS) Expects to Initiate Phase 2 STRAT-STAMPEDE Trial in 1H Evaluating Rucaparib in Prostate Cancer
Ticker: CLVS
Occurred on: Oct 21, 2018
Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer
Ticker: CLVS
Occurred on: Apr 06, 2018
Results from Phase 3 ARIEL3 maintenance treatment trial of rucaparib in advanced ovarian cancer patients will be highlighted at ESMO
Ticker: CLVS
Occurred on: Sep 07, 2017
Clovis (CLVS) Expects ARIEL3 Pivotal Maintenance Study Data in Mid-2017 Evaluating Rucaparib in Ovarian Cancer
Ticker: CLVS
Occurred on: May 23, 2017
Clovis (CLVS) Expects to Begin Enrolling Patients in Q1 2017 for Phase 1b Combination Study Evaluating Rucaparib with Genentech's (RHHBY) Tecentriq in Solid Tumors and Gynecologic Cancers
Tickers: CLVS, RHHBY, Genentech
Occurred on: May 03, 2017
Clovis (CLVS) Expects to Begin Phase 3 TRITON3 Study in Q1 Comparing Rucaparib to Physicians Choice of AR-Targeted Therapy or Chemotherapy in Treatment of Patients with Tumor BRCA Mutations and ATM Mutations
Ticker: CLVS
Occurred on: May 03, 2017
Clovis (CLVS) Discloses FDA Investigation into TIGER-X Study Evaluating Rociletinib in Lung Cancer
Ticker: CLVS
Occurred on: Feb 24, 2017
Clovis (CLVS) Plans to Initiate Phase 2 MITO-25 Study in Q1 Evaluating Rucaparib and Bevacizumab IIT in Ovarian Cancer 1L Maintenance
Ticker: CLVS
Occurred on: Feb 22, 2017
Rucaparib PDUFA Date assigned for February 23, 2017
Ticker: CLVS
Occurred on: Dec 19, 2016
Clovis' (CLVS) European Marketing Authorization Application (MAA) Submission for Rucaparib in ADHD Planned for Q4 2016
Ticker: CLVS
Occurred on: Nov 03, 2016
Clovis (CLVS) Presents Data on Two Phase 2 Studies of Rucaparib in Treatment-Resistant Ovarian Cancer at the European Society for Medical Oncology 2016 Congress
Ticker: CLVS
Occurred on: Oct 07, 2016
FDA Accepts Clovis Oncology’s New Drug Application for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer
Ticker: CLVS
Occurred on: Aug 23, 2016
TESARO's Niraparib Significantly Improved Progression-Free Survival for Patients With Ovarian Cancer in Both Cohorts of the Phase 3 NOVA Trial
Tickers: TSRO, CLVS
Occurred on: Jun 29, 2016
PDUFA March 30 2016 of Rociletinib for mutant EGFR T790M-positive lung cancer. Delay possible due to release of data during review cycle of much lower than expected overall response rates
Ticker: CLVS
Occurred on: Apr 12, 2016
Clovis Oncology Announces Rociletinib New Drug Application Scheduled for Presentation at Upcoming FDA Oncologic Drugs Advisory Committee Meeting on April 12, 2016
Ticker: CLVS
Occurred on: Apr 12, 2016
The ODAC meeting for reviewing rociletinib is scheduled to take place on April 12, 2016
Ticker: CLVS
Occurred on: Apr 08, 2016
FDA Posts Briefing Documents for Advisory Committee Meeting to Review Clovis Oncology’s Rociletinib for Treatment of Advanced T790M-Positive Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer
Ticker: CLVS
Occurred on: Apr 08, 2016

Strategic Initiatives (CLVS)

Clovis Oncology (CLVS) Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals (3BP)
Tickers: CLVS, 3BP
Announcement Date: Sep 23, 2019
Clovis Oncology (CLVS) and Immunomedics (IMMU) Announce Collaboration in Metastatic Triple-Negative Breast and Urothelial Cancers
Tickers: IMMU, CLVS
Announcement Date: Jun 03, 2018
Clovis (CLVS) Announces Collaboration Agreement with Myriad (MYGN) for a Companion Diagnostic Test for Germline BRCA Mutations
Tickers: CLVS, MYGN
Announcement Date: Apr 27, 2017

CLVS Overview